Article
BRAF V600E mutations are not an oncogenic driver of solitary xanthogranuloma and reticulohistiocytoma: Testing may be useful in screening for Erdheim-Chester disease.
Experimental and molecular pathology - 1 Dec 2019
Hoyt Brian S, Yan Shaofeng, Linos Konstantinos D, Momtahen Shabnam, Sriharan Aravindhan, Tran Tien-Anh N, Tsongalis Gregory J, O'Meara Rebecca R, Green Donald C, LeBlanc Robert E
Abstract excerpt
BRAF V600E is the predominant oncogenic driver of L-group histiocytoses, which includes Erdheim-Chester disease (ECD); however, limited data exist on the prevalence of this mutation in sporadic XG family lesions. This study sought to determine the incidence of BRAF V600E mutation in a clinically...
Topics
- Adolescent
- Adult
- Aged
- Biomarkers, Tumor
- Carcinogenesis
- Child
- Erdheim-Chester Disease
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Mutation
- Prognosis